Hikma Pharmaceuticals PLC 2022 AR2
The report highlights Hikma's financial and non-financial performance for 2022, showcasing a resilient core performance with Group revenue of $2,517 million. Key sustainability achievements include a 15% reduction in Scope 1 and 2 greenhouse gas emissions since the 2020 base year and a total of $4.3 million in donated medicines. The company also expanded its local manufacturing capacity in the MENA region and completed strategic acquisitions in the US and Canada to increase patient access to high-quality medicines. Additionally, Hikma maintained its membership in the FTSE4Good Index for the eighth consecutive year.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2022
Type: AR2
Pages: 103
Back to company
Hikma Pharmaceuticals PLC
Annual Report
The report highlights Hikma's financial and non-financial performance for 2022, showcasing a resilient core performance with Group revenue of $2,517 million. Key sustainability achievements include a 15% reduction in Scope 1 and 2 greenhouse gas emissions since the 2020 base year and a total of $4.3 million in donated medicines. The company also expanded its local manufacturing capacity in the MENA region and completed strategic acquisitions in the US and Canada to increase patient access to high-quality medicines. Additionally, Hikma maintained its membership in the FTSE4Good Index for the eighth consecutive year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Employees